Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Data may be intentionally delayed pursuant to supplier requirements. View today's stock price, news and analysis for Akebia Therapeutics Inc. (AKBA). Akebia Therapeutics presently has a consensus rating of Buy and an average price target of $9.75. AKBA 3.39 0.09 (2.73%). Find the latest press releases from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Akebia Therapeutics, (AKBA) disclosed a change of 5.00% and its listed share value at $2.73 in the recent trade transaction. By using this site you agree to the Post-Market 0.02 (0.59%) Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019© Refinitiv. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. There are currently no items in this Watchlist. If you are looking for stocks with good return, Akebia Therapeutics, Inc. stock can be a bad, high-risk 1-year investment option. If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. Source: Kantar Media. How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry, Akebia Shares Climb on Positive Anemia Drug Study Results, Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. International stock quotes are delayed as per exchange requirements. Source: FactSet. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Its products include Auryxia and Vadadustat. Intraday Data provided by FACTSET and subject to terms of use. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … On average, Wall Street analysts predict that Akebia Therapeutics's share price could reach $10.17 by Nov 11, 2021. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Intraday data delayed at least 15 minutes or per exchange requirements. Their average twelve-month price target is $10.29, predicting that the stock has a possible upside of 203.41%. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. For the best MarketWatch.com experience, please update to a modern browser. Since then, AKBA shares have decreased by 60.7% and is now trading at $2.73. Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue? Further, Akebia Therapeutics, Inc. (AKBA) has a beta value of 1.94, and an average true range (ATR) of 0.26. Akebia Therapeutics, Inc. is down ~75% from its 2020 highs after its oral anemia candidate vadadustat failed to achieve safety non-inferiority versus standard of care in CKD-NDD patients. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Get Our PREMIUM Forecast Now, from ONLY $6.69! Analysts have given the company’s stock an average 52-week price target of $6.71, forecast between a low of $3 and high of $10. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. The Stock rose vividly during the last session to $3.19 after opening rate of $3.16 while the lowest price it went was recorded $3.01 before closing at $3.08. Copyright 2019© FactSet Research Systems Inc. All rights reserved. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More, Akebia Falls as Vadadustat Fails to Meet Safety Endpoint, Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More, Implied Volatility Surging for Akebia (AKBA) Stock Options, Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates, Encompass Health Continues to Strengthen Presence in Florida. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Let’s start up with the current stock price of Akebia Therapeutics Inc. (AKBA), which is $3.15 to be very precise. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. The company’s stock price has collected 13.39% of gains in the last five trading sessions. The share float percentage for the stock currently stands at 81.57%. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Acadian Asset Management LLC lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 19,309.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Fundamental company data and analyst estimates provided by FactSet.

akebia therapeutics stock

Extra Large Space Blanket, Bad Dog Driving Range Orlando, Demarini Special Ops Wheeled Bag Reviews, 2300 Old Settlers Blvd, Round Rock, Tx 78665, Gin Cranberry Ginger Ale, Thai Hom Mali Jasmine Rice Recipe, Virginia Creeper Symptoms, 2d Projection Matrix, Professional Growth Books, Hella Bitters Kit, Quality Control Techniques Ppt, Richard Cadbury Introduced The First What In 1868, Divination In The Bible,
akebia therapeutics stock 2020